About Worldwide Clinical Trials
Operating across more than 60 countries, Worldwide Clinical Trials is a full-service contract research organisation built around a single discipline: clinical development. Founded in 1986, the company has spent nearly four decades focusing exclusively on Phase I through Phase IV studies, giving it a depth of therapeutic and regulatory expertise that generalist CROs rarely match.
The organisation is particularly well regarded for its work in central nervous system research, where it operates dedicated CNS units with specialist investigators and patient populations. Alongside CNS, Worldwide Clinical Trials carries strong capabilities in cardiovascular, metabolic, and rare disease development, areas where patient recruitment complexity and protocol design demand experienced hands.
Its Phase I infrastructure includes purpose-built clinical pharmacology units that support first-in-human studies, bioavailability and bioequivalence work, and early proof-of-concept programmes. This early-phase foundation connects seamlessly into its late-phase trial management, allowing sponsors to maintain a single CRO relationship from initial dosing through to regulatory submission.
Worldwide Clinical Trials works primarily with mid-size and emerging biopharmaceutical companies, positioning itself as a committed partner rather than a high-volume processor. That focus has earned it a reputation for therapeutic expertise and operational flexibility, qualities that sponsors managing complex or novel compounds tend to prioritise. Headquarters are in Wayne, Pennsylvania, with a global network of offices and clinical sites spanning North America, Europe, and beyond.
Further information is available at worldwide.com.
